Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
Serum samples from 194 cases and 217 controls participating in a case-control study of invasive cervical cancer in Brazil were examined for antibodies to human papillomavirus (HPV) 16 virus-like particles (VLPs) by ELISA. The prevalence of antibody in cases and controls was 47.4 versus 24.4% (P < 0.001). The prevalence was higher in women who had HPV-16 DNA in the genital tract (54.2%) than in those with other HPVs (36.8%) or no HPVs (44.8%), but the differences were not statistically significant. Among cases and controls, HPV-16 VLP antibodies were associated with a greater number of lifetime sexual partners (chi2 for trend, P < 0.001). Among controls, age was inversely associated with HPV-16 VLP seroreactivity (chi2 for trend, P = 0.019). The sera were previously tested for antibodies to HPV-16 E6 and E7 oncoproteins; there was no correlation between antibody titers to HPV-16 E6 or E7 and VLPs. The HPV-16 serological assays were compared as screening tests for invasive cervical cancer. The sensitivity and specificity estimates were 47.4 and 75.6% for HPV-16 VLP serology, 63.4 and 89.9% for either HPV-16 E6 or E7 serology, and 53.6 and 93.6% for high titers of either HPV-16 E6 or E7 or VLP antibodies. The utility of HPV-16 VLP ELISA as a screening test for invasive cervical cancer is limited by a high seroprevalence in women with probable prior exposure to HVP 16 but without disease.
Sun
Y
Y
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Eluf-Neto
J
J
Bosch
F X
FX
Muñoz
N
N
Walboomers
J M
JM
Meijer
C J
CJ
Shah
K V
KV
Clayman
B
B
Viscidi
R P
RP
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D001938:Brazil; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology*; D012097:Repressor Proteins; D014412:Tumor Virus Infections / Q000453:epidemiology / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000276:immunology*; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000276:immunology*
D000914:Antibodies, Viral; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16